Filter Lifespan in Continuous Renal Replacement Therapy

ConditionsCritically Ill Continuous Renal Replacement Therapy Infections

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUniversity Hospital Muenster

About this trial

The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (age ≥18 years)

Critically ill patients with dialysis-dependent AKI

Continuous renal replacement therapy (CRRT)

Written informed consent

Disqualifiers

Chronic kidney disease with estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2

Chronic dialysis dependency

Kidney transplant

(Glomerulo-)nephritis, interstitial nephritis, vasculitis

Trial population

Critically ill patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Critically ill patients with continuous renal replacement therapy
Procedure/Surgery
Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.

Treatment groups

No treatment groups listed